Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Interest ReceivablesChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Change in Working Capital: 2024-2025

  • Abivax's Change in Working Capital rose 60.87% to $2.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $5.8 million, marking a year-over-year change of. This contributed to the annual value of -$1.5 million for FY2024, which is 93.35% up from last year.
  • Abivax's Change in Working Capital amounted to $2.3 million in Q2 2025, which was up 288.66% from $593,263 recorded in Q1 2025.
  • Abivax's Change in Working Capital's 5-year high stood at $2.3 million during Q2 2025, with a 5-year trough of $593,263 in Q1 2025.
  • Over the past 2 years, Abivax's median Change in Working Capital value was $1.4 million (recorded in 2024), while the average stood at $1.4 million.
  • Over the last 5 years, Abivax's Change in Working Capital had its largest YoY gain of 60.87% in 2025, and its largest YoY loss of 58.15% in 2025.
  • Abivax's Change in Working Capital (Quarterly) stood at $1.4 million in 2024, then soared by 60.87% to $2.3 million in 2025.
  • Its Change in Working Capital was $2.3 million in Q2 2025, compared to $593,263 in Q1 2025 and $1.4 million in Q2 2024.